Search research articles
Contact Us
Filters
Showing results (51-60 of 135) with videos related to
Page
of 14
Sort By:
British Journal of Cancer
|
September 27, 2017
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M Hopkins, Andrew Rowland, Ganessan Kichenadasse, et al.
Investigational New Drugs
|
April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun A Azad, Howard Gurney, Craig Underhill, et al.
American Journal of Clinical Oncology
|
April 14, 2009
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer
Carmel Pezaro, Mark A Rosenthal, Howard Gurney, et al.
Journal of Translational Medicine
|
August 16, 2013
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia
Andreas Carus, Howard Gurney, Val Gebski, et al.
Endocrine Connections
|
April 17, 2019
A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy
Teresa Lam, Mark McLean, Amy Hayden, et al.
The Lancet Regional Health. Western Pacific
|
August 11, 2023
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study
Benjamin Daniels, Maria Aslam, Marina T van Leeuwen, et al.
Clinical Pharmacology and Therapeutics
|
January 8, 2005
Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer
Mark Wong, Scott Evans, Laurent P Rivory, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 21, 2021
Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center
Malmaruha Arasaratnam, Bavanthi Balakrishnar, Megan Crumbaker, et al.
Future Oncology (London, England)
|
October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Toni K Choueiri, Thomas Powles, Martin H Voss, et al.
Sports Medicine - Open
|
December 14, 2020
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Teresa Lam, Birinder Cheema, Amy Hayden, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 135) with videos related to
Sort By:
Page
of 14
British Journal of Cancer
|
September 27, 2017
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M Hopkins, Andrew Rowland, Ganessan Kichenadasse, et al.
Investigational New Drugs
|
April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun A Azad, Howard Gurney, Craig Underhill, et al.
American Journal of Clinical Oncology
|
April 14, 2009
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer
Carmel Pezaro, Mark A Rosenthal, Howard Gurney, et al.
Journal of Translational Medicine
|
August 16, 2013
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia
Andreas Carus, Howard Gurney, Val Gebski, et al.
Endocrine Connections
|
April 17, 2019
A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy
Teresa Lam, Mark McLean, Amy Hayden, et al.
The Lancet Regional Health. Western Pacific
|
August 11, 2023
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study
Benjamin Daniels, Maria Aslam, Marina T van Leeuwen, et al.
Clinical Pharmacology and Therapeutics
|
January 8, 2005
Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer
Mark Wong, Scott Evans, Laurent P Rivory, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 21, 2021
Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center
Malmaruha Arasaratnam, Bavanthi Balakrishnar, Megan Crumbaker, et al.
Future Oncology (London, England)
|
October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Toni K Choueiri, Thomas Powles, Martin H Voss, et al.
Sports Medicine - Open
|
December 14, 2020
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Teresa Lam, Birinder Cheema, Amy Hayden, et al.
Page
of 14